VectivBio Holding AG

Ironwood Pharmaceuticals’ future looks uncertain after it revealed on 14 April that the US Food and Drug Administration indicated that it will need to see a confirmatory Phase III trial on top of data

Ironwood Pharmaceuticals, Inc. appears to have a clear difference of opinion with shareholders after reporting Phase III data for short bowel syndrome with intestinal failure (SBS-IF) candidate aprag

The growing competition between Novo Nordisk and Eli Lilly in diabetes and obesity has been one of the biggest stories of 2023, and venture capital firm Forbion has been a major beneficiary, selli

The acquisition of Swiss biotech firm VectivBio Holding AG adds to Ironwood Pharmaceuticals, Inc. ’s pipeline a promising agent with a strong clinical program under its belt and a $1bn market potent